Detalles de la búsqueda
1.
Single-dose pharmacokinetics of mycophenolic acid following administration of immediate-release mycophenolate mofetil in healthy Beagle dogs.
J Vet Pharmacol Ther
; 44(4): 650-656, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33580714
2.
Mycophenolic acid in patients with immune-mediated inflammatory diseases: From humans to dogs.
J Vet Pharmacol Ther
; 42(2): 127-138, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-30375004
3.
Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone.
J Clin Psychopharmacol
; 30(1): 25-33, 2010 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-20075644
4.
Pharmacokinetics and Pharmacodynamics of Immediate- and Modified-Release Mycophenolic Acid Preparations in Healthy Beagle Dogs.
Front Vet Sci
; 7: 611404, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33585601
5.
Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence and absence of food.
BMC Clin Pharmacol
; 7: 2, 2007 Feb 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-17270055
6.
Pharmacokinetic investigation of dose proportionality with a 24-hour controlled-release formulation of hydromorphone.
BMC Clin Pharmacol
; 7: 3, 2007 Feb 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-17270058
7.
Characterisation of the pharmacokinetics of the fentanyl HCl patient-controlled transdermal system (PCTS): effect of current magnitude and multiple-day dosing and comparison with IV fentanyl administration.
Clin Pharmacokinet
; 44 Suppl 1: 7-15, 2005.
Artículo
en Inglés
| MEDLINE | ID: mdl-16156111
8.
The effect of dosing frequency on the pharmacokinetics of a fentanyl HCl patient-controlled transdermal system (PCTS).
Clin Pharmacokinet
; 44 Suppl 1: 17-24, 2005.
Artículo
en Inglés
| MEDLINE | ID: mdl-16156112
9.
Effects of application site and subject demographics on the pharmacokinetics of fentanyl HCl patient-controlled transdermal system (PCTS).
Clin Pharmacokinet
; 44 Suppl 1: 25-32, 2005.
Artículo
en Inglés
| MEDLINE | ID: mdl-16156113
10.
Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine.
J Clin Pharmacol
; 45(8): 961-8, 2005 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-16027408
11.
Evaluation of the bioequivalence of two transdermal fentanyl systems following single and repeat applications.
Curr Med Res Opin
; 21(12): 1961-8, 2005 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-16368047
12.
Effect of antacid on the pharmacokinetics of extended-release formulations of tolterodine and oxybutynin.
Clin Pharmacokinet
; 43(14): 1059-68, 2004.
Artículo
en Inglés
| MEDLINE | ID: mdl-15530134
13.
Randomized 5-treatment crossover study to assess the effects of external heat on serum fentanyl concentrations during treatment with transdermal fentanyl systems.
J Clin Pharmacol
; 52(8): 1174-85, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21878578
14.
Passive absorption of fentanyl from the fentanyl HCl iontophoretic transdermal system.
Curr Med Res Opin
; 25(2): 363-6, 2009 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19192980
15.
Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form.
Curr Med Res Opin
; 22(10): 1879-92, 2006 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-17022845
16.
New perspectives on the overactive bladder: pharmacokinetics and bioavailability.
Urology
; 60(5 Suppl 1): 78-80; discussion 80-1, 2002 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-12493362
17.
Pharmacokinetics of controlled-release verapamil in healthy volunteers and patients with hypertension or angina.
Biopharm Drug Dispos
; 23(1): 17-31, 2002 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-11891670
Resultados
1 -
17
de 17
1
Próxima >
>>